In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
Transcript
How are restrictive eligibility criteria contributing to keeping minority patients out of clinical trials?
So, we found within our cohort that African Americans were more likely to have kidney dysfunction compared with the white population. So, this means that clinical trials that include eligibility criteria that exclude patients with renal dysfunction may be disproportionately excluding patients with kidney disease, such as the African American patient population.
From a more broad perspective, this means that eligibility criteria may be systematically excluding African Americans from clinical trials because they have higher rates of renal dysfunction compared to the white patient population.
Are these restrictive eligibility criteria necessary or is there an argument to be made that these criteria should be relaxed?
So, for specific clinical trials it may still be appropriate to include restrictive eligibility criteria. So, I’ll give you an example. For clinical trials including interventions that are metabolized through the liver or excreted through the kidneys, it may be appropriate to still exclude patients who have minor liver or renal dysfunction.
However, for other clinical trials, our outcomes suggest that it may be appropriate to relax those eligibility criteria, and include patients who have minor renal or liver dysfunction as their outcomes are not significantly different than those patients who don’t have such abnormalities prior to the initiation of therapy.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More